Analysis of prognostic factors and construction of prognostic models for triple-positive breast cancer

Abstract

ObjectiveBy identifying the clinicopathological characteristics and prognostic influences of patients with triple-positive breast cancer (TPBC) at Xijing Hospital in China compared with those in the United States, this study aims to construct a nomogram model to forecast the overall survival rate (OS) of TPBC patients.MethodThe Surveillance, Epidemiology, and End Results (SEER) database was used to screen 5769 patients as the training cohort, and 191 patients from Xijing Hospital were used as the validation cohort. Cox risk-proportional model was applied to select variables and the nomogram model was constructed based on the training cohort. The performance of the model was evaluated by calculating the C-index and generating calibration plots in the training and validation cohorts.ResultsCox multifactorial analysis showed that age, chemotherapy, radiotherapy, M-stage, T-stage, N-stage, and the mode of surgery were all independent risk factors for the prognosis of TPBC patients (all P<0.05). With this premise, the nomogram model was constructed and evaluated. The C-index value of the nomogram model was 0.830 in the training group and 0.914 in the validation group. Moreover, both the calibration and ROC curves for the proposed model exhibited reliable performance, and the clinical decision curve analysis showed that the proposed model can bring clinical benefits.ConclusionsThe constructed nomogram can accurately predict individual survival probabilities and may serve as a clinical decision support tool for clinicians to optimize treatment in individuals.

Efficacy of everolimus‐based therapy in advanced triple‐positive breast cancer: Experience from three cancer centers in China

“…Selection of patients in the study. 5.1 months (95% CI: 0-13.0), showing no significance compared with 4.2 months (95% CI: 3.6-4.8) for patients who received everolimus + ET + anti-HER2 drug (p = 0.9). Censoring regimen of tyrosine kinase inhibitor (TKI) combinations, the median PFS for everolimus + chemotherapy + trastuzumab was estimated as 10.9 months (95% CI: 1.5-20.3), better than 3.7 months for everolimus + ET + trastuzumab (95% CI: 1.3-6.2).…”

“…4 Several studies have consistently shown that TPBC is highly invasive and exhibits increased proliferative activity. 5,6 TPBC patients generally present with higher tumor grades, larger tumor sizes, and an elevated risk of lymph node metastases. 5 There have been few studies on patients with TPBC, particularly for those at advanced stage disease.…”

“…5,6 TPBC patients generally present with higher tumor grades, larger tumor sizes, and an elevated risk of lymph node metastases. 5 There have been few studies on patients with TPBC, particularly for those at advanced stage disease. The primary treatment pattern for metastatic TPBC (mTPBC) is the combination of an anti-HER2 drug and chemotherapy, with or without endocrine therapy (ET).…”

“…TPBC has been classified as an independent biological subtype, with a poorer prognosis compared to HR‐positive (HR+)/HER2‐negative (HER2‐) subtype but a better prognosis than HR‐negative (HR‐)/HER2‐positive (HER2+) subtype 4 . Several studies have consistently shown that TPBC is highly invasive and exhibits increased proliferative activity 5,6 . TPBC patients generally present with higher tumor grades, larger tumor sizes, and an elevated risk of lymph node metastases 5 …”

“… 5 , 6 TPBC patients generally present with higher tumor grades, larger tumor sizes, and an elevated risk of lymph node metastases. 5 …”